Clinical Trials

Kadmon is developing innovative therapies for patients

To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov or email clinical@kadmon.com.

Autoimmune Disease: cGVHD

Brief

KD025 in patients with steroid-dependent or steroid-refractory cGVHD and active disease

Information
Phase: 2
Study Ref. #: KD025-208

Fibrotic Diseases: Idiopathic Pulmonary Fibrosis

Brief

KD025 in patients with IPF who have received or been offered pirfenidone and/or nintedanib

Information
Phase: 2
Study Ref. #: KD025-207

Autoimmune Disease: Psoriasis

Brief

Study to evaluate the safety, tolerability, and efficacy of KD025 in adult subjects with moderate to severe chronic plaque psoriasis

Information
Phase: 2
Study Ref. #: KD025-211

Monogenic Diseases: Autosomal Dominant Polycystic Kidney Disease

Brief

Tesevatinib in patients with autosomal dominant polycystic kidney disease

Information
Phase: 2
Study Ref. #: KD019-211

Tesevatinib in Autosomal Recessive Polycystic Kidney Disease

Brief

Tesevatinib liquid formulation in pediatric patients with ARPKD

Information
Phase: 1
Study Ref. #: KD019-103

Oncology: Glioblastoma

Brief

Study to assess tesevatinib in patients with recurrent glioblastoma

Information
Phase: 2
Study Ref. #: KD019-208

Oncology: Non-Small Cell Lung Cancer (NSCLC)

Brief

Study to assess tesevatinib in patients with NSCLC with activating EGFR mutations and brain metastases or leptomeningeal metastases

Information
Phase: 2
Study Ref. #: KD019-206